In head and neck squamous cell carcinoma (HNSCC), PD-L2 has been reported as an important predictor of progression-free survival for pembrolizumab, independent of PD-L1 status (57). This evidence concerns the gene PDCD1LG2 and head and neck squamous cell carcinoma.